基本信息
-
公司全称中山康方生物医药有限公司
-
类型创新型抗体药物研发商
-
产业领域药品研发/制造、生物药
-
公司人数500人以上
-
地址中山市火炬开发区神农路6号
-
联系电话0760-89873998
-
邮箱all@akesobio.com
-
成立时间2012-03-18
投融资
-
2024-10-13上市后再融资19.42亿港元未透露
-
2020-04-24IPO24.37亿港元未透露
-
2020-04-24上市24.37亿港元未透露
-
2020-04-14E~PreIPO1.63亿美元AIHC CapitalCRF Investment清池资本Hudson Bay Capital汉康医药博裕投资诚通基金富达国际奥博资本
-
2019-11-02D轮1.5亿美元建信资本杏泽资本奥博资本勤智资本深创投嘉华医疗中国生物制药国新国信东吴海外基金清池资本AIHC Capital交银国际正心谷创新资本
-
2019-11-02D轮1.5亿美元AIHC Capital清池资本正心谷资本嘉华医疗建信资本奥博资本杏泽资本国新国信东吴海外基金交银国际勤智资本深创投中国生物制药
-
2018-10-30C轮未透露汇桥资本集团建信资本勤智资本深创投
-
2018-10-30C轮超亿元人民币勤智资本深创投汇桥资本建信资本
-
2017-08-28B轮3亿人民币深创投前海母基金高特佳投资集团勤智资本
-
2017-08-28B轮3亿人民币高特佳投资深创投前海母基金勤智资本华兴资本
-
2015-11-23A轮1.3亿人民币深创投
-
2015-07-07A轮1.3亿人民币深创投
-
2012-03-19天使轮未透露建信资本
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司，开发工程化单体 IgA 中性粒细胞接合器，以释放中性粒细胞对癌症的肿瘤杀伤能力，以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心（荷兰乌得勒支）进行的开创性工作，并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息